Results 101 to 110 of about 83,328 (323)

Ipilimumab and Nivolumab-Induced Colitis in a Patient With Recurrent Metastatic Melanoma [PDF]

, 2021
Hamid-Reza Moein, Brian P. Rutledge, Rafic Beydoun, Murray N. Ehrinpreis   +3 more
openalex   +1 more source

Large Language Models for Clinical Trial Protocol Assessments

Clinical Pharmacology &Therapeutics, EarlyView.
The purpose was to evaluate the utility of large language models (LLMs) for reviewing the statistical analysis plan (SAP) and pharmacokinetics–pharmacodynamics (PK–PD) components of clinical trial protocols. Clinical trial protocols and SAPs were obtained from clinicaltrials.gov for a testbed of 15 small‐molecule drugs, biologics, and global antibiotic
Euibeom Shin, Amruta Gajanan Bhat, Murali Ramanathan   +2 more
wiley   +1 more source

Interference of the T cell and antigen-presenting cell costimulatory pathway using CTLA4-Ig (abatacept) prevents Staphylococcal enterotoxin B pathology [PDF]

, 2017
Staphylococcal enterotoxin B (SEB) is a bacterial superantigen that binds the receptors in the APC/T cell synapse and causes increased proliferation of T cells and a cytokine storm syndrome in vivo.
Carter, Alun J, Green, A. Christopher, Griffiths, Gareth D, Jones, James T.A., Rijpkema, Sjoerd, Risdall, Jane E, Saraiva, Luisa, Taylor, Chris, Vessillier, Sandrine, Whitfield, Sarah J.C., Williamson, E. Diane   +10 more
core   +2 more sources

Safety and Efficacy Findings From a Phase Ib/II Study of ASP‐1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Head &Neck, EarlyView.
ABSTRACT Background ASP‐1929 photoimmunotherapy—cetuximab conjugated to IRDye 700DX and red light (690 nm) for localized drug activation—results in rapid, selective cell killing. Methods This phase Ib/II open‐label study evaluated ASP‐1929 photoimmunotherapy plus pembrolizumab in patients with recurrent/metastatic HNSCC (≥ 1 accessible lesion, PD‐L1 ...
David M. Cognetti, Joseph M. Curry, Jennifer Johnson, Michael Kwon, Shirley Y. Su, Francisco Civantos, Coral Olazagasti, Joseph Valentino, Susanne M. Arnold, R. Bryan Bell, Michael K. Gibson, Kyle Mannion, Kathryn M. Van Abel, Katharine A. Price, Haiying Dong, Amy H. Thorne, Toshiaki Suzuki, Ann M. Gillenwater   +17 more
wiley   +1 more source

Herpes Encephalitis: A Mortal Complication in a Patient Treated with Immunosuppressive Drugs because of Immune-Related Adverse Events after Ipilimumab Treatment

Case Reports in Oncology, 2017
Until a few years ago, metastatic melanoma had a poor prognosis with limited treatment options. These therapeutics options and thereby median survival have increased obviously over 5 years with the arrival of immunotherapeutic drugs like ipilimumab ...
Lieke van Montfort, Caroline M. Loos, Monique Anten, Rob L.H. Jansen   +3 more
doaj   +1 more source

Potential role of immunotherapy in advanced non-small-cell lung cancer [PDF]

, 2016
Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib ...
Antoniou, Georgios, Catarina, Paulo Esrom, De Mello, Ramon Andrade, Nadine, Sara, Veloso, Ana Flavia   +4 more
core   +3 more sources

Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution [PDF]

, 2020
Ralf Kleef, Róbert Nagy, Andreas Baierl, V. Bacher, Hans Bojar, Dwight L. McKee, Ralph W. Moss, Nils H. Thoennissen, Attila Marcell Szász, Tibor Bakács   +9 more
openalex   +1 more source

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

Journal for ImmunoTherapy of Cancer, 2018
Background Nivolumab plus ipilimumab improves overall survival and is associated with less toxicity compared with sunitinib in the first-line setting of advanced renal-cell carcinoma (RCC).
Bin Wu, Qiang Zhang, Jie Sun
doaj   +1 more source

The use of drug calendars for the diagnosis of cutaneous drug eruptions in the age of electronic medical records [PDF]

, 2020
A morbilliform drug eruption is the most common condition leading to a dermatology consultation for a patient in the hospital. Timing is an important diagnostic tool since the onset of a skin rash usually takes place within days-to-weeks of the start of ...
Cohen, Philip R, Grossman, Marc E
core  

Head‐to‐head comparison of TKI and CPI first‐line treatment strategies in advanced renal cell carcinoma—Real‐world data from the German research platform CARAT

International Journal of Cancer, EarlyView.
What's New? The current standard of care for locally advanced or metastatic renal cell carcinoma (aRCC) is either a combination of two immune checkpoint inhibitors (CPI) or a CPI plus a tyrosine kinase inhibitor (TKI). Here, the authors simulate a head‐to‐head trial comparing the real‐world effectiveness of these combination therapies with TKI ...
Peter J. Goebell, Martin Bögemann, Arnd Nusch, Viktor Grünwald, Lothar Müller, Eyck von der Heyde, Uwe M. Martens, Carolin Lennartz, Michaela Koska, Karin Potthoff, Anja Kaiser‐Osterhues, Carsten Grüllich, Michael Staehler, Martina Jänicke, Dominik Marschner, the CARAT Registry Group   +15 more
wiley   +1 more source